12 SEP 2026 — Five-year results from the PROFILE trial, published in The Lancet, report that giving patients with newly diagnosed Crohn's disease an anti-TNF drug immediately rather than escalating to it produced fewer operations and cost less. Twenty-eight patients in the step-up group needed abdominal surgery against six in the top-down group.
The cost analysis found the immediate strategy saved £1,681 per patient while gaining 0.17 quality-adjusted life years. In health economics that combination has a name: it dominates.
The two strategies
Step-up is the conventional approach. A newly diagnosed patient starts on older, cheaper drugs, and treatment is escalated to a biologic if and when the disease proves it needs one. The logic is to avoid exposing people to a powerful drug they may not require.
Top-down inverts that. Infliximab, an anti-TNF biologic, plus an immunomodulator, from diagnosis.
PROFILE randomised 386 adults with newly diagnosed active Crohn's disease between the two, comparing top-down against an accelerated version of step-up rather than against a deliberately slow one. That comparison matters: the trial is not showing that early biologics beat neglect.
Why cheaper is the surprising half
The economic result is the one that changes policy. It removes the trade-off between better care and higher cost that everyone assumed existed.
A biologic given from diagnosis costs more at the moment of prescribing and less across five years. The arithmetic is straightforward. Abdominal surgery is expensive, and so is the hospital care around it. Twenty-two avoided operations across a 386-patient trial is a large enough difference to absorb a great many drug prescriptions.
That removes the usual reason for rationing early biologics, which is that a clinical benefit has to be weighed against a budget cost. On this evidence there is nothing to weigh.
How many are treated to prevent one operation
The trial randomised 386 people. Assuming the two arms were of roughly equal size, that is about 193 in each.
Twenty-eight operations in a group of 193 is about 14 per cent; six is about 3 per cent. The difference is a little over 11 percentage points, which means roughly nine patients need the top-down strategy for one of them to avoid an abdominal operation over five years.
A number-needed-to-treat of nine is low. Interventions for chronic diseases often run into the dozens or hundreds; a single-digit figure for an outcome as serious as bowel surgery is unusual. It also states the cost honestly: eight of those nine people take a biologic from diagnosis without avoiding an operation they would otherwise have had, which is precisely the exposure the step-up convention was designed to prevent — and the safety data above is what determines whether that exposure was harmful.
This arithmetic is ours, from the published counts. The trial's own reporting gives the surgery numbers rather than a number needed to treat, and a precise figure would require the exact arm sizes and follow-up, which we do not have.
The safety result deserves equal billing
The obvious objection to treating everyone aggressively from the start is that some of them did not need it and will be harmed by it.
At five years the trial reports no difference between the groups in serious infections — 7 per cent under step-up against 8 per cent under top-down — or in malignancies, at 3 per cent against 2 per cent. Those are the two harms anti-TNF therapy is most watched for, and the immunosuppression concern is the reason the step-up convention exists.
Two cautions belong with that. A single trial of 386 people at five years is not the design that detects a rare cancer signal, and the confidence intervals around percentages that close will overlap substantially. The trial found no difference in these harms, which is not the same as proving no difference exists.
What "disease modification" is claiming
The researchers frame the finding as disease modification, not just symptom control — a distinction central to the trial's purpose.
Symptom control means the patient feels better while on the drug. Disease modification means the long-term course of the illness has been altered — that the bowel damage which leads to surgery did not accumulate. The surgery count is what carries that claim, because an operation is a hard endpoint that does not depend on how a patient reports feeling on the day.
Five years supports the claim without settling it. Crohn's is a disease of decades, and whether the two curves stay apart at fifteen years is the question this result raises rather than settles.
What this means outside the trial's health system
The £1,681 saving is denominated in a currency and computed inside a health system with its own drug prices and its own surgical costs. Neither transfers directly.
Where infliximab biosimilars are cheap and hospital care is expensive, the economic case is stronger than the trial's own figure. Where the biologic is paid out of pocket or is not on a national formulary, the saving may exist at a system level while remaining out of reach of the individual patient — because the drug cost falls on the patient now and the avoided surgery falls on an insurer or the state later, which is a different pocket as well as a different decade.
For the individual patient, the economics are different. A treatment that saves the system money overall is still out of reach if the patient cannot afford the first prescription.
What to watch
Whether guidelines move. A five-year randomised result showing better outcomes at lower cost is the kind of evidence that changes a treatment algorithm, and the interval between this publication and a revised guideline is the measure of how quickly that machinery works.
And whether the curves hold. The value of the finding is in the long run, so the follow-up beyond five years is what converts disease modification from a well-supported claim into an established one.
This describes a randomised trial and is not medical advice. Treatment decisions in Crohn's disease depend on individual circumstances, and nothing here is a reason to start, stop or change a medication without a specialist.
View author profile → · Editorial policy
